Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Impacto
![Google Scholar](/xmlui/themes/Mirage2/images/uji/logo_google.png)
![Microsoft Academico](/xmlui/themes/Mirage2/images/uji/logo_microsoft.png)
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/7013
comunitat-uji-handle3:10234/8638
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humansAutoría
Fecha de publicación
2023-12-31Editor
ElsevierISSN
0753-3322Cita bibliográfica
Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez, Eulàlia Olesti, Natasha L. Mason, Johannes G. Ramaekers, Oscar J. Pozo, Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans, Biomedicine & Pharmacotherapy, Volume 169, 2023, 115775, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2023.115775.Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
https://www.sciencedirect.com/science/article/pii/S0753332223015731Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of ... [+]
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is needed when considering the development of future novel therapeutic approaches. Both metabolic and metabolomics studies may help for these purposes. On one hand, metabolic studies aim to determine the main metabolites of the drug. On the other hand, the application of metabolomics in human psychedelics studies can help to further understand the biological processes underlying the psychedelic state and the mechanisms of action underlying their therapeutic potential. This review presents the state of the art of metabolic and metabolomic studies after lysergic acid diethylamide (LSD), mescaline, N,N-dimethyltryptamine (DMT) and β-carboline alkaloids (ayahuasca brew), 5-methoxy-DMT and psilocybin administrations in humans. We first describe the characteristics of the published research. Afterward, we reviewed the main results obtained by both metabolic and metabolomics (if available) studies in classical psychedelics and we found out that metabolic and metabolomics studies in psychedelics progress at two different speeds. Thus, whereas the main metabolites for classical psychedelics have been robustly established, the main metabolic alterations induced by psychedelics need to be explored. The integration of metabolomics and pharmacokinetics for investigating the molecular interaction between psychedelics and multiple targets may open new avenues in understanding the therapeutic role of psychedelics. [-]
Publicado en
Biomedicine & Pharmacotherapy, Volume 169, 31 December 2023.Entidad financiadora
European Union-NextGenerationEU | Margarita Salas | Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Código del proyecto o subvención
MGS/2021/15, UP2021–021 | 406.18, FJC2018–035791-I, GO.019, MCIN/AEI/10.13039/501100011033
Derechos de acceso
© 2023 The Authors
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- QFA_Articles [825]